Comparing 3 Schedules of Alimta Plus Gemzar

Completed · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

In brief

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

Key facts

Study ID

NCT00034606

Run by

Eli Lilly and Company

Last updated by the study team

2006-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of non-small lung cancer
• No prior chemotherapy
• Able to care for self

You may not qualify if…

• An ongoing infection
• Pregnancy or breast feeding
• Other serious medical condition
• Cancer that has spread to the brain
• Inability to take folic acid

Where it is running

• Study site — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.